相关实验视频
Updated: Jun 15, 2026

07:22
Basophil Activation Test for Allergy Diagnosis
Published on: May 31, 2021
9.2K
蜜蜂毒的抗白血病潜力 蜜蜂毒的抗白血病潜力
Preeti Solanki1, Mohini Rana1, Karnail Singh Choudhary1
1Department of Biotechnology-UCRD, Chandigarh University, Mohali, Punjab, 140413, India.
International journal of general medicine
|December 15, 2025
概括
蜜蜂毒液 (BV) 显示出治疗白血病 (一种血液癌症) 的潜力. 研究表明,BV成分有效诱导癌细胞死亡并抑制生存途径,提供了一个有前途的替代或补充疗法.
科学领域:
- 阿皮疗法和癌症研究
- 血液学恶性瘤是什么
背景情况:
- 白血病是一种血液癌症,其特点是白细胞的异常产生,需要多模式治疗,如化疗和免疫疗法.
- 目前的白血病疗法面临的局限性包括耐药性,严重的副作用,高成本和遗传异质性,推动寻找替代品.
- 蜜蜂毒 (BV) 和其成分,特别是梅利丁,具有已被证明的抗癌特性,包括诱导亡和破坏细胞膜.
研究的目的:
- 审查当前关于治疗白血病中蜂毒疗法的有效性的体外研究.
- 评估蜜蜂毒素作为白血病独立或辅助治疗的潜力.
- 确定现有研究的局限性,并探索未来的研究方向,包括协同效应和有针对性的交付.
主要方法:
- 对实验室研究的系统综述,研究蜜蜂毒对各种人类白血病细胞系的影响 (例如HL-60,K562,Jurkat).
- 分析蜜蜂毒的作用机制,包括诱导细胞灭绝和抑制细胞生存途径 (例如,Akt/ERK).
- 评估蜜蜂毒药治疗剂量-时间和细胞系依赖的疗效.
主要成果:
- 蜜蜂毒液在多种白血病细胞系中表现出显著的抗白血病活性,这种活性取决于剂量和时间.
- 蜜蜂毒液的关键成分梅利,对白血病细胞具有强大的促细胞亡和抗增殖作用.
- 蜜蜂毒液有效抑制关键细胞生存信号通路,这表明它具有强大的抗癌机制.
结论:
- 蜜蜂毒是白血病治疗的有力候选者,在体外显著有效.
- 需要进一步研究蜜蜂毒与传统疗法和向输送系统的协同作用组合.
- 药用疗法为新型白血病治疗策略提供了一个有希望的途径,解决了当前方法的局限性.
相关概念视频
Cross-reactivity
Overview
Antibody Structure
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Hybridoma Technology
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...

